Valvular & structural heart disease
10-Year Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement or Surgery in Intermediate-Risk Patients
Main finding · All-cause mortalityResult — go to the resultHazard ratio 1.01 95% CI 0.91–1.13Authors' conclusion
At 10 years, TAVR with the SAPIEN 3 valve and surgery resulted in similar rates of mortality and aortic valve reintervention, and similar hemodynamics in intermediate-risk patients with symptomatic severe aortic stenosis.
Study context
- Population
- Intermediate-risk patients with symptomatic severe ASmatched n = 783 per group
- Participants
- 2,005 patients
- Exposure
- SAPIEN 3 transcatheter aortic valve replacement (TAVR) vs surgical AVR
- TAVRn = 1,069
- Surgeryn = 936reference
- Outcome
- All-cause mortality, aortic valve reintervention and core lab-adjudicated echocardiographic outcomes
- Follow-up
- 10 years
Methodological detailsP2A, multicentre, Reconsent required at 5 years for 10-year follow-up; vital status sweeps for mortality completeness
- P2A
- Multicentre
- Reconsent required at 5 years for 10-year follow-up; vital status sweeps for mortality completeness
Main finding
All-cause mortality
Hazard ratio
1.01
95% CI 0.91–1.13
P = 0.82
By group
TAVRvs Surgery
HR 1.01 (95% CI 0.91–1.13); P = 0.82
As reported in the abstract
Observational data: associations, not effects.
Further findings
Aortic valve reintervention (adjusted for competing mortality) · 10 years
P = 0.47
Mean aortic valve gradient · 10 years
- Mean aortic valve gradient: echo data available in 32 TAVR and 30 surgical patients
Original publication
10-Year Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement or Surgery in Intermediate-Risk Patients. J Am Coll Cardiol. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →